Vivos Therapeutics Q1 2026 Earnings Report

Vivos Therapeutics EPS Results

• Actual EPS: -$0.52
• Consensus EPS: -$0.45
• Beat/Miss: Missed by -$0.07
• One Year Ago EPS: N/A

Vivos Therapeutics Revenue Results

• Actual Revenue: $5.14 million
• Expected Revenue: $4.35 million
• Beat/Miss: Beat by +$792.00 thousand
• YoY Revenue Growth: N/A

Vivos Therapeutics Announcement Details

• Quarter: Q1 2026
• Date: 5/20/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Vivos Therapeutics (NASDAQ:VVOS) is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol. Clinicians are guided through patient assessment, imaging and diagnostic procedures, appliance design and fitting, and ongoing monitoring. In addition to device manufacturing, Vivos Therapeutics provides comprehensive training and certification programs for dental professionals, enabling a standardized approach to screening, treatment planning, and patient follow-up within the Vivos network.

Headquartered in Lone Tree, Colorado, Vivos Therapeutics markets its solutions through a network of licensed dental practitioners across the United States and select international regions, including Canada, Europe and parts of Asia-Pacific. The company continues to expand its footprint by partnering with accredited educational institutions and professional societies to promote awareness of oral appliance therapy as a first-line intervention for airway health.